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A B S T R A C T
Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disorder affecting young children. The
natural course of JMML is rapidly fatal with 80% of patients surviving less than three years. Allogeneic hematopoietic
stem cell transplantation (HSCT) is the only curative treatment of JMML. We report a case of a 23-month-old girl who
presented with an upper respiratory tract infection, fever, rash, diarrhea, hepatosplenomegaly and abdominal distention.
Severe elevation of white blood cell count with monocytosis and myeloid progenitors in the peripheral blood was also de-
tected. Bone marrow smear showed morphology suggestive of JMML, an unspecific immune phenotype and a normal
karyotype. DNA analysis revealed a mutation in the PTPN11 gene. Therefore, the final diagnosis of JMML with somatic
PTPN11 mutation was established. Following three months of cytostatic therapy with 6-mercaptopurine and low doses
of cytarabine partial remission was achieved and allogeneic HSCT was successfully performed. Six months after the di-
agnosis, the girl was in a good condition and in a complete remission of JMML. Early diagnosis and allogeneic HSCT
were crucial for successful treatment outcome.
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Introduction
Juvenile myelomonocytic leukemia (JMML) is a rare
type of childhood leukemia representing 2% of hemato-
poietic malignancies in childhood. It is a stem cell disor-
der characterized by clonal hyperproliferation of mono-
cytes and granulocytes without differentiation arrest1.
The World Health Organization has included JMML in
the category of Myelodysplastic and Myeloproliferative
disorders2. It is characterized by young age, hepatosple-
nomegaly, lymphadenopathy accompanied by infiltration
of other organs, particularly lungs, intestines and skin3.
The natural course of JMML is rapidly fatal with 80% of
patients surviving less than three years4. The only cura-
tive treatment modality for these children is allogeneic
HSCT, with event-free survival in about half of the
children5.
Here we report a case of 23-month-old girl diagnosed
with JMML and somatic PTPN11 mutation.
Case Report
A 23-month-old girl was admitted to our hospital due
to upper respiratory tract infection accompanied with
prolonged fever, rash, diarrhea and abdominal disten-
sion. Family history showed a pattern of malignancies,
with the grandfather on the father’s side dying from
chronic lymphocytic leukemia and both grandparents on
the mother’s side dying from solid tumors. The mother
was 37 years old at delivery. The patient is her second
child after two miscarriages. The pregnancy and delivery
were without complications. Birth was at term and in-
fancy period was without any serious illnesses.
Initial physical examination did not reveal hepato-
splenomegaly. But hepatosplenomegaly rapidly develo-
ped within the first week of admission, together with en-
larged mesenterial and retroperitoneal lymph nodes.
Initial workup revealed severe increase in white blood
cell (WBC) count (up to 71.33´109/L) with monocytosis
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(25% of WBC) and myeloid progenitors present in the pe-
ripheral blood (Figure 1a). Serological testing and DNA
analysis ruled out acute Epstein-Barr virus, cytomegalo-
virus, human herpesvirus 6 and toxoplasma infection.
Hemoglobin F was also increased (10.1%). Subsequently,
bone marrow smear showed morphology suggestive of
JMML: high cellularity, M:E ratio of 15:1, left shift,
hyperplastic myelopoiesis with hypergranulation and
moderate dysplasia, hypoplastic erythropoiesis and mild
dysplastic megakaryopoiesis. Microscopic bone marrow
differential count showed blasts (4%), promyelocytes
(7%), myelocytes (22%), metamyelocytes (15%), bands
(12%), segmented (17%), eosinophils (1%), basophils
(1%), lymphocytes (7%), monocytes (8%) and erythro-
blasts (6%) (Figure 1b). Bone marrow analysis demon-
strated an unspecific immune phenotype and a normal
karyotype. The patient was negative for the Philadelphia
chromosome and the BCR/ABL fusion gene. In further
studies monocyte infiltration was detected in an endo-
scopic ultrasound guided biopsy of a mesenterial lymph
node (Figure 2). DNA analysis revealed a mutation in the
PTPN11 gene, exon 3, G226A.
Consequently, the patient was diagnosed with JMML
and allogeneic HSCT was suggested as the only curative
treatment. Therefore, HLA typing of the patient and
family members was performed. Her older sister was
found to be a suitable bone marrow donor. The patient
was treated with three courses of cytarabine (5 days, 75
mg/m2per day, subcutaneously administered) and contin-
uous 6-mercaptopurine (50 mg/m2 per day, given orally)
which resulted in normalization of WBC count and a de-
crease in liver, spleen and lymph nodes size. During che-
motherapy she received depleted and irradiated platelet
transfusions twice. Two months after the diagnosis of
JMML had been established, following three courses of
chemotherapy, the girl was referred to another hospital
in a clinically stable condition and in a partial remission.
Sequencing her buccal swab DNA did not show a muta-
tion in PTPN11, exon 3, excluding germline PTPN11
mutation. Also a new bone marrow aspiration was per-
formed: bone marrow was hypercellular demonstrating a
left-shifted trilineage hematopoiesis. Occasional mega-
karyocytes were found. Moderate myeloid and mild ery-
throid dysplasia, with M:E ratio of 1.2:1, were observed
with occasional hemophagocytosis. Microscopic differen-
tial count showed blasts (8%), promyelocytes (2%), mye-
locytes (8%), metamyelocytes (1%), stabs (12%), seg-
mented (17%), eosinophiles (1%), basophiles (0%), mono-
cytes (1%), lymphocytes (13%) and erythroid progenitors
(37%). This time cytogenetics showed a 3q duplication in
2/17 metaphases and a normal female karyotype in 15/17
metaphases.
JMML with somatic PTPN11 mutation was confir-
med. Preparative regimen, based on the use of busulfan
(20 mg/kg given orally over 4 consecutive days), cyclo-
phosphamide (60 mg/kg per day for 2 consecutive days)
and melphalan (140 mg/m2 in a single dose), preceded a
family related allogeneic HSCT (done according to the
EWOG-MDS/EBMT protocol) which was successfully
performed three months after the initial diagnosis. Six
months after the diagnosis was established, the patient’s
condition was satisfactory and she showed no signs of
JMML.
Discussion
JMML is a rare type of childhood leukemia character-
ized by young age, hepatosplenomegaly, lymphadeno-
pathy accompanied by infiltration of other organs, espe-
cially lungs, intestines and skin3. Splenomegaly invaria-
bly develops rapidly in the course of this disease, creating
abdominal distension with considerable discomfort. Dry
cough and tachypnea are caused by lung infiltration.
WBC count is mostly elevated, but in contrast to chronic
myelogenous leukemia (CML) rarely exceeds 100´109/L.
Since prompt diagnosis is not always simple to make,
morphological evaluation of the peripheral blood smear
is often crucial. It demonstrates monocytosis with imma-
ture and dysplastic forms. An absolute monocyte count of
1000/mL is a prerequisite for the diagnosis6. Blasts may
be present in the peripheral blood but their percentage is
less than 20%3.
Two-thirds of JMML patients have the reversal to fe-
tal red cell characteristics, including increased levels of
hemoglobin F, expression of the i antigen and low car-
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Fig. 1. Monocytes (May-Grünwald-Giemsa) in a) peripheral
blood and b) the bone marrow aspirate smear.
Fig. 2. The leukemic infiltrate in the fine needle aspirate of the
lymph node (monocytes): a) May-Grünwald-Giemsa, b) alpha
naphthyl acetate esterase and c) immunocytochemical staining
with CD68.
bonic anhydrase levels7. Therefore, hemoglobin electro-
phoresis may help establish the diagnosis. Many infec-
tious diseases caused by Epstein-Barr virus, cytomegalo-
virus, human herpesvirus 6, histoplasma, mycobacteria,
and toxoplasma can closely mimic JMML and further
complicate the diagnostic procedure6.
JMML lacks the Philadelphia chromosome and the
BCR/ABL fusion gene. Chromosomal studies of leukemic
cells show monosomy 7 in about 25%, other abnormali-
ties in 10% and a normal karyotype in 65% of pa-
tients3,8,9. Myeloid progenitors also show hypersensitiv-
ity for granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF)10. It is mediated by the RAS-RAF-MAP
(mitogen-activated protein) kinase signaling pathway,
which is patologically activated by mutations in RAS,
NF1 (the gene for neurofibromatosis 1), and PTPN11.
These mutually exclusive mutations in JMML suggest
the importance of the pathological activation of RAS de-
pendent pathways in the pathophysiology of the disease4.
Somatic mutations in PTPN11, the gene encoding the
protein tyrosine phosphatase SHP2, are the most fre-
quent molecular lesions in JMML and are encountered in
approximately 35% of all JMML patients11. However, it is
important to note that about half of children with Noo-
nan syndrome are known to carry specific germline mu-
tation in PTPN1112 and that JMML-like myeloprolife-
rative disorder has occurred in some of these children13.
The natural course of JMML is rapidly fatal. Progres-
sion to blast crisis is infrequent, but most children die
from progressive respiratory and organ failure. The only
curative treatment option for these children is allogeneic
HSCT5. It is important to rule out or confirm the possi-
bility of Noonan syndrome in newly-diagnosed children
with JMML and, if a PTPN11mutation is present, deter-
mine whether the mutation is somatic or germline. The
JMML-like disorder may spontaneously disappear in the
patients with Noonan syndrome and PTPN11 germline
mutation. Therefore, reasonable therapy for these chil-
dren is close observation4.
Despite JMML being a rare disease, it has well de-
fined diagnostic guidelines. Splenomegaly, monocytosis
(>1´109/L) in the peripheral blood and less than 20% of
blasts in the bone marrow are the essential clinical and
hematological criteria for JMML. In patients fulfilling
these criteria the diagnosis of JMML is further facili-
tated by the presence of one of the following: PTPN11/
RAS/NF1 mutation, clinical diagnosis of neurofibroma-
tosis 1 (NF1) or monosomy 7. The diagnosis of JMML in
patients without the PTPN11/RAS/NF1 mutation, clini-
cal diagnosis of NF1 or monosomy 7 should be made by
employing the standard criteria. Colony assay for sponta-
neous growth and hypersensitivity to GM-CSF, as well as
the exclusion of BCR/ABL rearrangement are manda-
tory for those patients6. Prognosis of the disease has
been associated with three characteristic areas: sex of
the patient, age at diagnosis and other existing condi-
tions. Males, younger than 2 and with a diagnosed Noo-
nan syndrome have been shown to have a more encour-
aging prognosis. Also, low platelet count and high HbF at
diagnosis have been found to be predictors of short
survival3,8,14.
Our patient had splenomegaly, monocytosis (>1´109/L)
in the peripheral blood, less than 20% of blasts in the
bone marrow and a PTPN11 mutation, which was suffi-
cient to establish the diagnosis. The patient had no ele-
ments of Noonan syndrome phenotype which commonly
includes heart malformation, short stature, learning dis-
abilities, indentation of the chest, impaired blood clot-
ting and facial changes12. We also sequenced her buccal
swab DNA which excluded germline mutation and
JMML-like disorder. Detailed testing for a panel of infec-
tious diseases ruled out an infectious origin of the clinical
and hematologic symptoms. All those investigations
were necessary prior to HSCT because JMML-like disor-
der can spontaneously disappear without any treatment.
It is also important to point out that standard chemo-
therapy, regardless of the intensity, has been proven ef-
fective only in a small number of patients4. Systematic
evaluation of chemotherapeutic approaches in JMML is
difficult due to the lack of standardized response criteria
and the heterogeneity of response (i.e., clearance of leu-
kemic cells from bone marrow but not solid organs, or
vice versa). It appears that 6-mercaptopurine is an agent
that consistently produces clinical and/or hematologic
improvement, either alone or combined with cytarabine
or etoposide15. In vitro 13-cis-retinoic acid has been pro-
ven to inhibit the growth of JMML cells. Hence, the COG
JMML Study included it in the treatment protocol. Nev-
ertheless, therapeutic value of 13-cis-retinoic acid for
JMML still remains controversial16. Our patient respon-
ded well to combination of low doses of cytarabine and
6-mercaptopurine which resulted in a partial remission
with normalization of WBC count and a decrease in liver,
spleen and lymph nodes sizes. However, a cytological fol-
low-up analysis of the bone marrow, after two months of
treatment, still showed JMML with the appearance of
chromosome aberration. This further contributes to the
belief that the allogeneic HSCT is in fact the only cura-
tive therapy for JMML and that children diagnosed with
JMML should be treated with an allogeneic bone marrow
transplant as soon as a suitable donor is found4.
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JUVENILNA MIJELOMONOCITNA LEUKEMIJA S PTPN11 MUTACIJOM KOD DJEVOJ^ICE
STARE 23 MJESECA
S A @ E T A K
Juvenilna mijelomonocitna leukemija (JMML) je rijetki klonalni mijeloproliferativni poreme}aj od kojeg obolijevaju
djeca. Prirodni tijek JMML-a brzo zavr{ava fatalno i 80% pacijenata pre`ivi manje od tri godine. Alogena transplan-
tacija hematopoetskih mati~nih stanica jedini je kurativni tretman za JMML. Predstavljamo slu~aj djevoj~ice stare 23
mjeseca hospitalizirane zbog infekcije gornjih di{nih putova, vru}ice, osipa, proljeva, hepatosplenomegalije i distendira-
nog abdomena. Bila je prisutna zna~ajno povi{ena razina leukocita s monocitozom i mijeloidnim progenitorima u peri-
fernoj krvi. Analiza razmaza ko{tane sr`i pokazala je morfologiju karakteristi~nu za JMML, nespecifi~an imunolo{ki
fenotip i normalan kariotip. DNA analizom dokazana je mutacija u PTPN11 genu. Time je postavljena kona~na dijag-
noza JMML-a sa somatskom mutacijom PTPN11 gena. Nakon tromjese~ne terapije 6-merkaptopurinom i niskim doza-
ma citarabina, provedena je alogena transplantacija hematopoetskih mati~nih stanica. [est mjeseci nakon postavljanja
dijagnoze pacijentica je u dobrom stanju i kompletnoj remisiji bolesti. Rana dijagnoza i alogena transplantacija hemato-
poetskih mati~nih stanica su od osnovne va`nosti za uspje{an ishod lije~enja.
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